Pfizer drug helps stop progression of breast cancer


Pfizer's (PFE) Palbociclib treatment doubled progression-free survival to 20.2 months in a Phase 2 trial of 165 patients with advanced breast cancer.

Palbociclib also helped patients live four months longer, although the result isn't statistically significant.

Palbociclib is part of a new class of drug called CDK 4/6 inhibitors, which limit the activity of two enzymes involved in cell division — cyclin-dependent kinases 4 and 6.

Palbociclib is considered a potential blockbuster that could be used with other cancers, and it is forecast to sell $3.11B by 2020. Amgen (AMGN) would receive an 8% royalty on any sales. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs